3847 |
Upcoming Trend in ACS Patient Management |
Roxana Mehran |
Apr. 21. 16 |
3846 |
MitraClip Will Be the Dominant Therapy in Severe FMR - Predicting COAPT |
Ted Feldman |
Apr. 21. 16 |
3845 |
The DAPT Duration Debate - Practical Synthesis and Clinical Recommendations |
Roxana Mehran |
Apr. 21. 16 |
3844 |
PARTNER 2A - TAVR in Intermediate Risk Patients |
Martin Bert Leon |
Apr. 21. 16 |
3843 |
From STABLE to PREVENT [2] |
Seung-Jung Park |
Apr. 21. 16 |
3842 |
LEADERS-FREE - Which DES in High Bleeding Risk Patients? |
Philip M. Urban |
Apr. 21. 16 |
3841 |
Focal Vulnerable Plaque Stabilization by Scaffold Treatment |
Evelyn Regar |
Apr. 21. 16 |
3840 |
ABSORB III - Current and Future Use of Bioresorbable Scaffolds |
Gregg W. Stone |
Apr. 21. 16 |
3839 |
Current and Future Imaging Diagnosis of Vulnerable Plaque |
Akiko Maehara |
Apr. 21. 16 |
3838 |
Zilver PTX Stent for CLI - Insights from the Japan Post Market Study |
Hiroyoshi Yokoi |
Apr. 21. 16 |